Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Total revenues	$ 1,663,405	$ 1,111,795	$ 1,173,751
Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Total revenues	486,100	115,700
Manufacturing Revenue
Disaggregation Of Revenue [Line Items]
Total revenues	142,498	112,374	105,628
Manufacturing Revenue | VUMERITY
Disaggregation Of Revenue [Line Items]
Total revenues	42,886	32,493	25,808
Manufacturing Revenue | RISPERDAL CONSTA
Disaggregation Of Revenue [Line Items]
Total revenues	36,123	42,670	40,413
Manufacturing Revenue | Other
Disaggregation Of Revenue [Line Items]
Total revenues	63,489	37,211	39,407
Royalty
Disaggregation Of Revenue [Line Items]
Total revenues	600,890	219,609	436,179
Royalty | Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Total revenues	486,101	115,655	303,106
Royalty | VUMERITY
Disaggregation Of Revenue [Line Items]
Total revenues	86,440	83,003	61,614
Royalty | RISPERDAL CONSTA
Disaggregation Of Revenue [Line Items]
Total revenues	1,153	7,243	10,456
Royalty | Other
Disaggregation Of Revenue [Line Items]
Total revenues	27,196	13,708	61,003
Manufacturing and royalty revenues
Disaggregation Of Revenue [Line Items]
Total revenues	743,388	331,983	541,807
Manufacturing and royalty revenues | Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Total revenues	486,101	115,655	303,106
Manufacturing and royalty revenues | VUMERITY
Disaggregation Of Revenue [Line Items]
Total revenues	129,326	115,496	87,422
Manufacturing and royalty revenues | RISPERDAL CONSTA
Disaggregation Of Revenue [Line Items]
Total revenues	37,276	49,913	50,869
Manufacturing and royalty revenues | Other
Disaggregation Of Revenue [Line Items]
Total revenues	$ 90,685	$ 50,919	$ 100,410